Intas Biopharma Acquires Biologics Process Development
Intas Biopharmaceuticals Limited (IBPL, Ahmedabad, India) has acquired the US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc., Poway, CA).
Intas Biopharmaceuticals Limited (IBPL, Ahmedabad, India) has acquired the US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc., Poway, CA). With the acquisition process underway, both companies are actively pursuing plans to work closely toward fulfillment of common business objectives in the area of contract research and manufacturing services (CRAMS). With agreement in the final stages of completion, the financials have been undisclosed and will be announced at a later stage.
The development will facilitate and assist Intas Biopharmaceuticals Limited’s foray in the US market, especially to expand its CRAMS business. Scott M. Brown, PhD, will continue as president and chief scientific officer of BPD Inc., and Rajeev Datar, PhD, will be the new chief executive officer of BPD Inc.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
